Real Progress for Dermatology’s Most Commonly Overlooked Conditions

The treatment of common dermatologic and aesthetic conditions is at a turning point. For too long, innovation has lagged – leaving patients underserved and clinicians without the tools they need to deliver transformative care.

Veradermics is changing this.

LEARN MORE

About

The company’s lead candidate under evaluation, VDPHL01, has the potential to become the first non-hormonal oral therapy designed and studied specifically for men and women with Pattern Hair Loss (PHL).

Veradermics, Inc. is an aesthetics and dermatology-focused biopharmaceutical company advancing first-in-class therapeutics that address common real-world patient needs in under-innovated markets.

Veradermics Raises $75 Million in Series B Financing and Initiates Phase 2/3 Trial for Hair Loss

Veradermics Male Pattern Baldness Treatment

Dermatologists Developing First-in-Class Drugs For Dermatology

Addressing Common Real-World Patient Needs in Under-Innovated Markets

BOLD STRATEGY

Advancing novel therapeutics for common everyday conditions, to meet real-world needs that have inexplicably lacked treatment innovation, and to transform care in underserved treatment domains.

LEARN MORE

DEEP PIPELINE

A dynamic pipeline of innovative therapies with the potential to set new standards of care – targeting first-in-class opportunities that have the potential to set new, attainable benchmarks.

LEARN MORE

PROVEN EXPERTISE

Differentiated pipeline curated by leveraging executive team’s front-line clinical experience as board-certified dermatologists

LEARN MORE

Veradermics is advancing a bold and diverse pipeline of novel therapies designed to reimagine care for both adults and children—targeting widespread conditions long overdue for innovation. From androgenetic alopecia and common warts to molluscum contagiosum, alopecia areata, and atopic dermatitis, we’re committed to delivering meaningful breakthroughs where patients need them most.